435 related articles for article (PubMed ID: 32341788)
1. Hypertrophic cardiomyopathy in myosin-binding protein C (
Adalsteinsdottir B; Burke M; Maron BJ; Danielsen R; Lopez B; Diez J; Jarolim P; Seidman J; Seidman CE; Ho CY; Gunnarsson GT
Open Heart; 2020; 7(1):e001220. PubMed ID: 32341788
[TBL] [Abstract][Full Text] [Related]
2. Clinical Characteristics and Long-Term Outcome of Hypertrophic Cardiomyopathy in Individuals With a MYBPC3 (Myosin-Binding Protein C) Founder Mutation.
van Velzen HG; Schinkel AFL; Oldenburg RA; van Slegtenhorst MA; Frohn-Mulder IME; van der Velden J; Michels M
Circ Cardiovasc Genet; 2017 Aug; 10(4):. PubMed ID: 28794111
[TBL] [Abstract][Full Text] [Related]
3. Nationwide study on hypertrophic cardiomyopathy in Iceland: evidence of a MYBPC3 founder mutation.
Adalsteinsdottir B; Teekakirikul P; Maron BJ; Burke MA; Gudbjartsson DF; Holm H; Stefansson K; DePalma SR; Mazaika E; McDonough B; Danielsen R; Seidman JG; Seidman CE; Gunnarsson GT
Circulation; 2014 Sep; 130(14):1158-67. PubMed ID: 25078086
[TBL] [Abstract][Full Text] [Related]
4. Diastolic abnormalities as the first feature of hypertrophic cardiomyopathy in Dutch myosin-binding protein C founder mutations.
Michels M; Soliman OI; Kofflard MJ; Hoedemaekers YM; Dooijes D; Majoor-Krakauer D; ten Cate FJ
JACC Cardiovasc Imaging; 2009 Jan; 2(1):58-64. PubMed ID: 19356534
[TBL] [Abstract][Full Text] [Related]
5. The Burden of Early Phenotypes and the Influence of Wall Thickness in Hypertrophic Cardiomyopathy Mutation Carriers: Findings From the HCMNet Study.
Ho CY; Day SM; Colan SD; Russell MW; Towbin JA; Sherrid MV; Canter CE; Jefferies JL; Murphy AM; Cirino AL; Abraham TP; Taylor M; Mestroni L; Bluemke DA; Jarolim P; Shi L; Sleeper LA; Seidman CE; Orav EJ;
JAMA Cardiol; 2017 Apr; 2(4):419-428. PubMed ID: 28241245
[TBL] [Abstract][Full Text] [Related]
6. Founder mutation in myosin-binding protein C with an early onset and a high penetrance in males.
Méndez I; Fernández AI; Espinosa MÁ; Cuenca S; Lorca R; Rodríguez JF; Tamargo M; García-Montero M; Gómez C; Vilches S; Vázquez N; Álvarez R; Medrano C; Yotti R; Fernández-Avilés F; Bermejo J
Open Heart; 2021 Sep; 8(2):. PubMed ID: 34588271
[TBL] [Abstract][Full Text] [Related]
7. A founder MYBPC3 mutation results in HCM with a high risk of sudden death after the fourth decade of life.
Calore C; De Bortoli M; Romualdi C; Lorenzon A; Angelini A; Basso C; Thiene G; Iliceto S; Rampazzo A; Melacini P
J Med Genet; 2015 May; 52(5):338-47. PubMed ID: 25740977
[TBL] [Abstract][Full Text] [Related]
8. T1 measurements identify extracellular volume expansion in hypertrophic cardiomyopathy sarcomere mutation carriers with and without left ventricular hypertrophy.
Ho CY; Abbasi SA; Neilan TG; Shah RV; Chen Y; Heydari B; Cirino AL; Lakdawala NK; Orav EJ; González A; López B; Díez J; Jerosch-Herold M; Kwong RY
Circ Cardiovasc Imaging; 2013 May; 6(3):415-22. PubMed ID: 23549607
[TBL] [Abstract][Full Text] [Related]
9. Cardiovascular magnetic resonance of mitral valve length in hypertrophic cardiomyopathy.
Tarkiainen M; Sipola P; Jalanko M; Heliö T; Laine M; Järvinen V; Häyrinen K; Lauerma K; Kuusisto J
J Cardiovasc Magn Reson; 2016 Jun; 18(1):33. PubMed ID: 27259862
[TBL] [Abstract][Full Text] [Related]
10. A human MYBPC3 mutation appearing about 10 centuries ago results in a hypertrophic cardiomyopathy with delayed onset, moderate evolution but with a risk of sudden death.
Teirlinck CH; Senni F; Malti RE; Majoor-Krakauer D; Fellmann F; Millat G; André-Fouët X; Pernot F; Stumpf M; Boutarin J; Bouvagnet P
BMC Med Genet; 2012 Nov; 13():105. PubMed ID: 23140321
[TBL] [Abstract][Full Text] [Related]
11. Development of left ventricular hypertrophy in adults in hypertrophic cardiomyopathy caused by cardiac myosin-binding protein C gene mutations.
Maron BJ; Niimura H; Casey SA; Soper MK; Wright GB; Seidman JG; Seidman CE
J Am Coll Cardiol; 2001 Aug; 38(2):315-21. PubMed ID: 11499718
[TBL] [Abstract][Full Text] [Related]
12. Compound heterozygosity deteriorates phenotypes of hypertrophic cardiomyopathy with founder MYBPC3 mutation: evidence from patients and zebrafish models.
Hodatsu A; Konno T; Hayashi K; Funada A; Fujita T; Nagata Y; Fujino N; Kawashiri MA; Yamagishi M
Am J Physiol Heart Circ Physiol; 2014 Dec; 307(11):H1594-604. PubMed ID: 25281569
[TBL] [Abstract][Full Text] [Related]
13. Genetic polymorphisms in the renin-angiotensin-aldosterone system associated with expression of left ventricular hypertrophy in hypertrophic cardiomyopathy: a study of five polymorphic genes in a family with a disease causing mutation in the myosin binding protein C gene.
Ortlepp JR; Vosberg HP; Reith S; Ohme F; Mahon NG; Schröder D; Klues HG; Hanrath P; McKenna WJ
Heart; 2002 Mar; 87(3):270-5. PubMed ID: 11847170
[TBL] [Abstract][Full Text] [Related]
14. Novel electrocardiographic features in carriers of hypertrophic cardiomyopathy causing sarcomeric mutations.
Jalanko M; Heliö T; Mustonen P; Kokkonen J; Huhtala H; Laine M; Jääskeläinen P; Tarkiainen M; Lauerma K; Sipola P; Laakso M; Kuusisto J; Nikus K
J Electrocardiol; 2018; 51(6):983-989. PubMed ID: 30497761
[TBL] [Abstract][Full Text] [Related]
15. CMR derived left ventricular septal convexity in carriers of the hypertrophic cardiomyopathy-causing MYBPC3-Q1061X mutation.
Tarkiainen M; Sipola P; Jalanko M; Heliö T; Jääskeläinen P; Kivelä K; Laine M; Lauerma K; Kuusisto J
Sci Rep; 2019 Apr; 9(1):5960. PubMed ID: 30976029
[TBL] [Abstract][Full Text] [Related]
16. Diltiazem treatment for pre-clinical hypertrophic cardiomyopathy sarcomere mutation carriers: a pilot randomized trial to modify disease expression.
Ho CY; Lakdawala NK; Cirino AL; Lipshultz SE; Sparks E; Abbasi SA; Kwong RY; Antman EM; Semsarian C; González A; López B; Diez J; Orav EJ; Colan SD; Seidman CE
JACC Heart Fail; 2015 Feb; 3(2):180-8. PubMed ID: 25543971
[TBL] [Abstract][Full Text] [Related]
17. Electrocardiographic features of sarcomere mutation carriers with and without clinically overt hypertrophic cardiomyopathy.
Lakdawala NK; Thune JJ; Maron BJ; Cirino AL; Havndrup O; Bundgaard H; Christiansen M; Carlsen CM; Dorval JF; Kwong RY; Colan SD; Køber LV; Ho CY
Am J Cardiol; 2011 Dec; 108(11):1606-13. PubMed ID: 21943931
[TBL] [Abstract][Full Text] [Related]
18. The Metabolome in Finnish Carriers of the MYBPC3-Q1061X Mutation for Hypertrophic Cardiomyopathy.
Jørgenrud B; Jalanko M; Heliö T; Jääskeläinen P; Laine M; Hilvo M; Nieminen MS; Laakso M; Hyötyläinen T; Orešič M; Kuusisto J
PLoS One; 2015; 10(8):e0134184. PubMed ID: 26267065
[TBL] [Abstract][Full Text] [Related]
19. Association of variants in MYH7, MYBPC3 and TNNT2 with sudden cardiac death-related risk factors in Brazilian patients with hypertrophic cardiomyopathy.
Mori AA; Castro LR; Bortolin RH; Bastos GM; Oliveira VF; Ferreira GM; Hirata TDC; Fajardo CM; Sampaio MF; Moreira DAR; Pachón-Mateos JC; Correia EB; Sousa AGMR; Brión M; Carracedo A; Hirata RDC; Hirata MH
Forensic Sci Int Genet; 2021 May; 52():102478. PubMed ID: 33588347
[TBL] [Abstract][Full Text] [Related]
20. Phenotypic spectrum of the first Belgian
Boen HM; Alaerts M; Van Laer L; Saenen JB; Goovaerts I; Bastianen J; Koopman P; Vanduynhoven P; De Vuyst E; Rosseel M; Heidbuchel H; Van Craenenbroeck EM; Loeys B
Front Genet; 2024; 15():1392527. PubMed ID: 38836037
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
